Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 Ml;HR5l1d3SxeHnjJGF{e2G7 NVGwd|NoOTBibl2= M2T4[FczKGh? NVewV2EyTE2VTx?= M3LWXnBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> M4nud|I1QTByOEez
HT-29 MX\DfZRwfG:6aXOgRZN{[Xl? MkfYNVAhdk1? MXK3NkBp NH3xZZpFVVOR MWLQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? M3K4NVI1QTByOEez
HT-29 NYPUWJZqS3m2b4TvfIlkKEG|c3H5 NY\rSVRMOTBibl2= M3ztcVczKGh? NH:ybVdFVVOR M1XWVHBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MX[yOFkxODh5Mx?=
PC3 M1;nWWtqdmG|ZTDBd5NigQ>? MlrONVAxKG6P M3nrVVEhcA>? MkWzSG1UVw>? NE\nRYVRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> NFPSeHAzOTl5OE[4Ny=>
PC3 MlXjT4lv[XOnIFHzd4F6 M13DT|ExOCCwTR?= MWGxJIg> MkfmSG1UVw>? MYHEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MVqyNVk4QDZ6Mx?=
PC3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSxMlUh|ryP M4G0eFEhcA>? Mn2zSG1UVw>? M2LvV2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NGfKbpEzOTl5OE[4Ny=>
HEK293 M13LW2Z2dmO2aX;uJGF{e2G7 MX6xNFAhdk1? NFW1dFA5KGh? NYXvSoFwTE2VTx?= M3LPPWlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= MmX0NlE2Ozl|MEG=
BT-20 MXPLbY5ie2ViQYPzZZk> NHv3NYozOCEQvF2= Mlf2SG1UVw>? MV;Ec4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? M4fSSlIyOzV|NUWx
U937 NVrac5BpSW62aXLhZ5RmemmjbDDBd5NigQ>? MYS1NEDPxE1? MnjMOFghcA>? NVr6VYtbTE2VTx?= MkX0TY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| NX:yfGJbOjFzNEKxNFY>
U937 NH[y[2pCdnSrYnHjeIVzcWGuIFHzd4F6 MVu1NEDPxE1? NVXnS45rPDhiaB?= MUfEUXNQ MoLBSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? Mo[xNlEyPDJzME[=
U937 NVzX[nZ{SW62aXLhZ5RmemmjbDDBd5NigQ>? NVX5OY1FPTBizszN MWC0PEBp M2[yOGROW09? NGrFOZhFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? MUCyNVE1OjFyNh?=
MCF-7 NIG2[pdCfXSxcHjh[5khSXO|YYm= MVWzNEBvVQ>? MkDhOEBp NHvjeIJFVVOR M1rjN2lv\HWlZYOgZZV1d3CqYXf5 NUnFbnNrOjByMkixN|Q>
U87MG Mlu0T4lv[XOnIFHzd4F6 M1Xic|Eh|ryP NHTpUXc3KGh? MYrEUXNQ M3npWXBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w MWexPVg1QDRyNB?=
U87MG NVq5OIRpU2mwYYPlJGF{e2G7 MWexJO69VQ>? MnznOkBp NVzjZoZMTE2VTx?= NG\1c41Rd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> MVqxPVg1QDRyNB?=
U87MG NXPjWGFLU2mwYYPlJGF{e2G7 MnHJNUDPxE1? MonCOkBp NWC5[VM2TE2VTx?= NFq4[JhFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= MUGxPVg1QDRyNB?=
U87MG M{Hhc2tqdmG|ZTDBd5NigQ>? M165WFEh|ryP MnraOkBp MXrEUXNQ MX\Ec4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NV\sdJBnOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb M3LZSWF2fG:yaHHnfUBCe3OjeR?= MVWwMlIh|ryP Mn70NlQhcA>? MnjHSG1UVw>? NEX0d4RKdmS3Y3XzJIF2fG:yaHHnfS=> NImxR3YyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 NU\O[pRqSXW2b4DoZYd6KEG|c3H5 M3jDUFAvOiEQvF2= NXO5fphZOjRiaB?= M1LLR2ROW09? NXPZbotnUW6mdXPld{BifXSxcHjh[5k> NYWwN2ZHOTh|OUG5OFk>
H4 M3jRbmZ2dmO2aX;uJGF{e2G7 MVuwMlIh|ryP MnrWNlQhcA>? M3GzdmROW09? M1viOmlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> M2Pwe|E5ODJ2NUi0
HeLa NXXSdY9uTnWwY4Tpc44hSXO|YYm= NFXkUVQyODBibl2= M3nReFM3KGh? NYnJd24zTE2VTx?= NFXZW3lKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v M3HqfVE4PTZ|M{i1
HeLa MkT1SpVv[3Srb36gRZN{[Xl? NYLlc|hiOTByIH7N NFXib2c{PiCq NIXNWYhFVVOR M1vvfGlv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NXO2epg2OTd3NkOzPFU>
HeLa NYW2XYlXTnWwY4Tpc44hSXO|YYm= MlnWNVAxKG6P Mk\LN|YhcA>? M{fhTGROW09? NEXKbVJKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NXzNbHhoOTd3NkOzPFU>
SYF MoPkSpVv[3Srb36gRZN{[Xl? M{HvOVExOCCwTR?= M3nrelI1KGh? MnjPSG1UVw>? M2POV2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NFfMWYUyPzV4M{O4OS=>
SYF NVTnbVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvJNVAxKG6P NVzV[W1kOjRiaB?= MYnEUXNQ M{jzSmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= M2PuNVE4PTZ|M{i1
HEK293T NYfRenJuSW62aY\pdoFtKEG|c3H5 M1LUZlEhdk1? M{Gxb|Qh\A>? MV7EUXNQ MXjJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= M3nzZlE4PDh3NUCx
HEK293T MV;BcpRqfmm{YXygRZN{[Xl? MmC4NUBvVQ>? Ml3POEBl MorOSG1UVw>? NITUTZBKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MVqxO|Q5PTVyMR?=
PBMC Mn23SpVv[3Srb36gRZN{[Xl? NWjyWpVxOSCwTR?= NULITld{OTRiZB?= MUPEUXNQ NVKxeVVMWmWmdXPld{BES1J3IHTlcpNqfHl? NF7MbHcyPzR6NUWwNS=>
PBMC NHvHem9HfW6ldHnvckBCe3OjeR?= MnXkNUBvVQ>? NFO3UXoyPCCm MYHEUXNQ NInTTIlFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? MnfGNVc1QDV3MEG=
HEK293 cells MlnET4lv[XOnIFHzd4F6 MkPmOVAhdk1? Mke2OFUhdWmw NVT3SZF5TE2VTx?= M1vqTGlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? NXfoTYxPOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NX;uTo04TnWwY4Tpc44hSXO|YYm= MlT0NVAxKG6P NYr4VFNTPCCq NWX3dHhITE2VTx?= MW\JcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> M2XQVlE4OTJ6Mk[y
Human mixed lymphocyte NHHPV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnxdFR6PSCwTR?= MoPYSG1UVw>? NXrOcmVDUUN3ME2xMlYhdk1w NHSwS5UyPjF6NUi2OS=>
Lewis rat lymph node cells MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInxbGU2KM7:TR?= M{LVOWROW09? MofZTWM2OD1{Lk[g{txO MUCxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice NGC1e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH1[WZyOTBibl2= NFrUWos4OiCq NVzJTmdYTE2VTx?= M3zmRmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= NX\mTGd4OTByMkG5OFg>
MRK-nu-1 M2\jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zBeWlEPTB;MD64OFUheE1? NIfuWHpUSU6JRWK=
OCUB-M NY\xOmNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwMkSgdG0> M{XnR3NCVkeHUh?=
SF539 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13xS2lEPTB;MUGuOkBxVQ>? NF;RN|ZUSU6JRWK=
ES4 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJzLkWgdG0> NXrpSYpmW0GQR1XS
RL95-2 M{PQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm0cGRzUUN3ME2xNFcheE1? M1rrPXNCVkeHUh?=
LC-2-ad MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXPTWM2OD12MkOgdG0> MmLxV2FPT0WU
Daudi MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLtXnFKSzVyPUSzOEBxVQ>? NI\LR25USU6JRWK=
NTERA-S-cl-D1 MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDZd4NKSzVyPUS0N{BxVQ>? MV;TRW5ITVJ?
OS-RC-2 NH;JUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DJWGlEPTB;NkWyJJBO MV;TRW5ITVJ?
VA-ES-BJ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjVN4NKSzVyPUeyN{BxVQ>? NEOxV2VUSU6JRWK=
GR-ST M1nQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSyR4tKSzVyPUi0OkBxVQ>? Ml6xV2FPT0WU
SW872 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTh2NjDwUS=> M3rabnNCVkeHUh?=
NOS-1 NGHQZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTh5MTDwUS=> MojmV2FPT0WU
MC116 NGTBeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXzXmxKSzVyPUm4OUBxVQ>? M{K3VHNCVkeHUh?=
NCI-H1355 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwMEGgcm0> NFSydZRUSU6JRWK=
RPMI-8226 NFzRc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwMUmgcm0> MkHIV2FPT0WU
TE-15 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi0TWM2OD1zLkO2JI5O NX61PW9TW0GQR1XS
Ramos-2G6-4C10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\KW2lEPTB;MT60OkBvVQ>? M2D5dXNCVkeHUh?=
KU812 NWPoR3VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37iV2lEPTB;Mj6wNUBvVQ>? MljRV2FPT0WU
EW-1 M{[5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj0cZFLUUN3ME2yMlE4KG6P NFSwclZUSU6JRWK=
KS-1 NGDyT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwNEWgcm0> NGjFVopUSU6JRWK=
SK-LMS-1 NH6yNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFqxVZhKSzVyPUKuOFkhdk1? MXfTRW5ITVJ?
TGBC1TKB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwNkmgcm0> MW\TRW5ITVJ?
TE-6 NWjqV4MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;DTWM2OD1{Lke3JI5O MYnTRW5ITVJ?
ETK-1 M4DuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwOEKgcm0> NV;FNXNCW0GQR1XS
BE-13 M{DUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLXWlFKSzVyPUKuPVkhdk1? NUPKfXpqW0GQR1XS
A3-KAW NX;TRpNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7ue5BDUUN3ME2yMlk6KG6P MUfTRW5ITVJ?
TE-10 NIfVOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDjeZk5UUN3ME2zMlMhdk1? M{mzdHNCVkeHUh?=
DOHH-2 NVPLb3RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfsTJdVUUN3ME2zMlM2KG6P MYHTRW5ITVJ?
ES6 NWm0R2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\PTGlEPTB;Mz60N{BvVQ>? M4TYO3NCVkeHUh?=
OPM-2 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7DTWM2OD12LkG1JI5O MnHrV2FPT0WU
SH-4 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwM{Sgcm0> NHf6OYFUSU6JRWK=
NB13 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHPTWM2OD12LkO2JI5O MnfQV2FPT0WU
HUTU-80 M4XLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXmTWM2OD12LkSyJI5O MmfzV2FPT0WU
CCRF-CEM NInMSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwOUSgcm0> NH[4O|ZUSU6JRWK=
TGBC24TKB M13oUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC0TWM2OD13LkWxJI5O MkS2V2FPT0WU
697 NXXpWVdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonWTWM2OD14LkK4JI5O M4Dp[nNCVkeHUh?=
J-RT3-T3-5 NXTuWWY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y0dmlEPTB;Nj60OkBvVQ>? NILaV4FUSU6JRWK=
KALS-1 NWmzTGJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fTb2lEPTB;Nj61OkBvVQ>? M1nSSHNCVkeHUh?=
no-10 NYXxNFhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTdwMkmgcm0> NXy0d5lQW0GQR1XS
SK-NEP-1 NWnhfY12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRThwN{mgcm0> MoD5V2FPT0WU
L-540 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzpTWM2OD1zMD60NkBvVQ>? NVi5SYI4W0GQR1XS
JiyoyeP-2003 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLXTWM2OD1zMD65OEBvVQ>? MWHTRW5ITVJ?
HH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jlPGlEPTB;MUGuN|khdk1? MUXTRW5ITVJ?
SR NHLTWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFzLkS1JI5O MoPOV2FPT0WU
QIMR-WIL MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFzLki1JI5O NGLh[IRUSU6JRWK=
A4-Fuk NHTwZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvyTJduUUN3ME2xN{4yOiCwTR?= MVLTRW5ITVJ?
CESS M3rzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF|LkGzJI5O NIHIXIdUSU6JRWK=
KE-37 M4HQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxd2lEPTB;MU[uNFchdk1? MUfTRW5ITVJ?
SK-UT-1 NVy4bWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHLTWM2OD1zNj64NUBvVQ>? M162WXNCVkeHUh?=
SIG-M5 NX7ke3M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF5LkK1JI5O MmfsV2FPT0WU
HT MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3exdmlEPTB;MUeuOkBvVQ>? NGS0UZRUSU6JRWK=
DEL MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;KTWM2OD1zNz65PUBvVQ>? M1XvcnNCVkeHUh?=
SK-PN-DW NXTmU20{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj1d3pJUUN3ME2yNE4zOyCwTR?= NU\MNIdZW0GQR1XS
RPMI-8402 M37OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjpcnhKSzVyPUKxMlc4KG6P M2T3ZXNCVkeHUh?=
RPMI-6666 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTzW4hMUUN3ME2yOE41OiCwTR?= NVe5XW5zW0GQR1XS
NCI-H720 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzmXXBKSzVyPUK1MlQyKG6P M4DzR3NCVkeHUh?=
EW-16 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK1TWM2OD1{Nj64O{BvVQ>? M{\BdHNCVkeHUh?=
BL-70 M2i3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\GcIs4UUN3ME2yPE4{QCCwTR?= NF3NTGlUSU6JRWK=
SF126 NFfkZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv5bZpKSzVyPUOwMlM5KG6P NInmVoxUSU6JRWK=
BC-1 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDJelNKSzVyPUOxMlI3KG6P M{G3SnNCVkeHUh?=
MHH-PREB-1 M3rXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mwZWlEPTB;M{KuOFQhdk1? MnHuV2FPT0WU
A101D NUXHOVFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrrS2VGUUN3ME2zNk43OiCwTR?= NYPhb4M6W0GQR1XS
NMC-G1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DC[WlEPTB;M{OuOlchdk1? M{jTSHNCVkeHUh?=
LB1047-RCC NUXKOnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nwWWlEPTB;M{SuOlkhdk1? MXTTRW5ITVJ?
EM-2 M1jJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H1N2lEPTB;M{iuOVMhdk1? NXLLc5ptW0GQR1XS
COLO-684 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi0fIxbUUN3ME2zPU45KG6P M4C2XXNCVkeHUh?=
Becker M37rSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;KOmlEPTB;NEGuNFUhdk1? MoqwV2FPT0WU
BL-41 M1raOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDNPY5KSzVyPUSzMlY3KG6P NYHs[WtwW0GQR1XS
MDA-MB-134-VI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnZTWM2OD12ND6wNkBvVQ>? NILzdW5USU6JRWK=
L-363 NWnDWphZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjE[4hVUUN3ME20OE44OyCwTR?= M1rHOXNCVkeHUh?=
ECC4 M4[5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTR2Lke4JI5O NFTvOYxUSU6JRWK=
A388 NULtcJIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR2LkiyJI5O NIrlXoJUSU6JRWK=
HEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7P[oEzUUN3ME20PU44QSCwTR?= NETQeGxUSU6JRWK=
RKO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTVyLkK5JI5O M2LpXnNCVkeHUh?=
KINGS-1 NX[yWnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ORWlEPTB;NUGuOVUhdk1? NUiyTJZpW0GQR1XS
EB-3 NULRRWdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTV{Lk[3JI5O M3jpUXNCVkeHUh?=
ARH-77 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\zNWFHUUN3ME21Nk45KG6P NYfX[YRzW0GQR1XS
GCIY NILI[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\3VWlEPTB;NUOuOFYhdk1? NX22Z|JWW0GQR1XS
NCI-H1304 NWPmVndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDs[2tKSzVyPUW3MlIzKG6P MVfTRW5ITVJ?
KARPAS-299 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfSXnViUUN3ME22NU45OiCwTR?= NEHaOG1USU6JRWK=
IA-LM NYXjOmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTZ6LkGzJI5O NXvpc5c5W0GQR1XS
GI-1 NYTSWFA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTdyLkO5JI5O MXnTRW5ITVJ?
TE-11 NXT1TpdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTd5LkG3JI5O M3Tle3NCVkeHUh?=
LS-411N NVPEeolVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP4WmZKSzVyPUe3MlU4KG6P MWHTRW5ITVJ?
no-11 NHnMUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW1TWM2OD16Mz6yOEBvVQ>? NH;Ee5RUSU6JRWK=
MV-4-11 M3zzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzy[FFlUUN3ME24N{44OyCwTR?= MVPTRW5ITVJ?
BV-173 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r0UmlEPTB;OEOuPVchdk1? MoniV2FPT0WU
CMK NEPWOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TL[WlEPTB;OESuNVYhdk1? NX7tSpFZW0GQR1XS
LC4-1 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nMemlEPTB;OE[uO|Ihdk1? M1X3UHNCVkeHUh?=
COR-L279 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn64TWM2OD16Nz6yOUBvVQ>? NYrwTZVHW0GQR1XS
NCI-H209 NHjw[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThZmdVUUN3ME24O{41OSCwTR?= MVrTRW5ITVJ?
Raji NUPUeItOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTh7LkeyJI5O M4q5UHNCVkeHUh?=
LB996-RCC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;nXGtKSzVyPUmzMlQ{KG6P MYHTRW5ITVJ?
NCI-H526 M1ToWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDXTWM2OD17Mz61PUBvVQ>? MkjEV2FPT0WU
KGN MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG3UVlKSzVyPUm2MlI6KG6P Ml7KV2FPT0WU
MOLT-4 NGDFS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLHWJM1UUN3ME25Ok44QSCwTR?= MV3TRW5ITVJ?
PF-382 M33DcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTl4Lke5JI5O M4DnU3NCVkeHUh?=
BC-3 NYPLdmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTl7LkG4JI5O M4O5SHNCVkeHUh?=
KARPAS-422 NFq5SVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyMj6wPUBvVQ>? MXPTRW5ITVJ?
SBC-1 NYPPcJVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7qeWF{UUN3ME2xNFcvPzVibl2= NX;sOpVKW0GQR1XS
LC-1F NU\GRVJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljxTWM2OD1zMEiuNFUhdk1? MVHTRW5ITVJ?
GB-1 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TUTWlEPTB;MUC5MlAzKG6P MljPV2FPT0WU
SNB75 MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmxW4MxUUN3ME2xNVkvPjlibl2= NGrFNHdUSU6JRWK=
BB65-RCC M3LWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnYU|I3UUN3ME2xNVkvQTNibl2= M1jBb3NCVkeHUh?=
NCI-N87 NYTsdlVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnjTWM2OD1zMkGuPVghdk1? NEn1OXlUSU6JRWK=
IST-MEL1 NFiy[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH72[nZKSzVyPUGyNk4{QCCwTR?= M{TFTHNCVkeHUh?=
HOP-62 NXq3SpRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfjOVFKSzVyPUGyOk45QSCwTR?= MlnlV2FPT0WU
ACN MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO4dHBKSzVyPUG0Ok44PSCwTR?= NGLaS4hUSU6JRWK=
DMS-114 M2\DRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn3O5pKUUN3ME2xOVAvPjdibl2= NEnVZZlUSU6JRWK=
MLMA NWPVRVFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nNbWlEPTB;MUW5Mlg5KG6P NX3MeZF5W0GQR1XS
HT-144 M{\aSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLIc5MxUUN3ME2xOlUvPDNibl2= NGPuPVNUSU6JRWK=
C2BBe1 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Gw[GlEPTB;MU[3Mlc3KG6P MoDhV2FPT0WU
L-428 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF5Nz63JI5O NHXO[WdUSU6JRWK=
DU-4475 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPFZmJKSzVyPUG4O{43QCCwTR?= MXTTRW5ITVJ?
CP67-MEL MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm5VHpKSzVyPUG5PU4{QCCwTR?= NH\1fJRUSU6JRWK=
MEG-01 NHHHR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HZSGlEPTB;MkCxMlk3KG6P NYjmU5pIW0GQR1XS
IST-SL2 M2\uO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjWTWM2OD1{MEiuOlMhdk1? MV3TRW5ITVJ?
ES8 M{SzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWiyOXJ2UUN3ME2yNlUvQTRibl2= NGTQdFFUSU6JRWK=
COLO-800 NEfnXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\zRXNKSzVyPUKzOU4zQCCwTR?= MVLTRW5ITVJ?
MFH-ino M3\YTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvuWHNKSzVyPUKzOU45PCCwTR?= NEX4TlhUSU6JRWK=
OVCAR-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTxdZBHUUN3ME2yN|cvOjRibl2= NEf4UWZUSU6JRWK=
PSN1 NXnW[Vg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNPWNmUUN3ME2yOFIvPzFibl2= M{HNfHNCVkeHUh?=
EW-12 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTDWmg5UUN3ME2yOFMvOSCwTR?= NXLjWmU{W0GQR1XS
HCC1599 M{HiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ4MT60O{BvVQ>? MVfTRW5ITVJ?
SJSA-1 NYr5e4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjlTmNKUUN3ME2yO|EvPDZibl2= MmLZV2FPT0WU
ST486 NWjWW2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ7Nj6xOEBvVQ>? MoLWV2FPT0WU
NOMO-1 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrqTWM2OD1|MECuNlEhdk1? NVrwTHFPW0GQR1XS
MN-60 M{LBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrQU3ZKSzVyPUOwOU4{OiCwTR?= NEDKVYZUSU6JRWK=
HCC1187 NGLPV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7nTWM2OD1|MEeuNlUhdk1? NYG1NJpHW0GQR1XS
SW982 M2rJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDaTWM2OD1|MUSuO|Uhdk1? NWLWcVh5W0GQR1XS
LB647-SCLC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH1N5FZUUN3ME2zNlgvPzFibl2= MnzaV2FPT0WU
HC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTPeoZKSzVyPUOzOU42KG6P MnnQV2FPT0WU
EHEB M1f0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[xTWM2OD1|M{euOVIhdk1? NGLyepVUSU6JRWK=
TUR M3z2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN4Mz65OUBvVQ>? MULTRW5ITVJ?
LU-139 NFHvdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PS[mlEPTB;M{e4MlAzKG6P MnjuV2FPT0WU
NB1 NVr0SW9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L4OWlEPTB;M{i0MlQ2KG6P M2DsPHNCVkeHUh?=
BB30-HNC MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHftVJRKSzVyPUO4PE4{OiCwTR?= MonkV2FPT0WU
HAL-01 NFXRZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSxTWM2OD1|OEmuNlYhdk1? NGLQeVVUSU6JRWK=
K5 NUjsZXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nBXGlEPTB;NEGxMlM4KG6P NGLuVWtUSU6JRWK=
MZ2-MEL MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zvbmlEPTB;NEGzMlY1KG6P M{D1VHNCVkeHUh?=
RXF393 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT6cXdKSzVyPUSxOk41PSCwTR?= NVfEXlBZW0GQR1XS
NCI-H1648 NXfie3RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG5TWM2OD12MUeuOVMhdk1? NYf3WnpuW0GQR1XS
TE-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX3PIlKSzVyPUSzOE4zPiCwTR?= MUjTRW5ITVJ?
EoL-1- NWPCfFE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXiNoNOUUN3ME20N|cvQThibl2= NF;aNYRUSU6JRWK=
JAR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR|OD62NkBvVQ>? NWPNfJlyW0GQR1XS
DSH1 M3y0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhTWM2OD12NUiuPVEhdk1? NGC5SFlUSU6JRWK=
NCI-H187 NXfndZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3hTWM2OD12NkKuPFEhdk1? NYjIRXVuW0GQR1XS
HCE-4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTjTWM2OD12N{euOlYhdk1? M{j3TXNCVkeHUh?=
8-MG-BA MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXVPIlTUUN3ME21PFEvPTJibl2= NUDwO3NMW0GQR1XS
KLE NH3OSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LqS2lEPTB;NUi1MlIhdk1? NUGxb2FqW0GQR1XS
KNS-42 NXe1NHRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTV6Nj64NUBvVQ>? M4TuXXNCVkeHUh?=
MSTO-211H MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHIdlI4UUN3ME22NFkvPzRibl2= NH;X[W1USU6JRWK=
GDM-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInwbmxKSzVyPU[xOE4xQSCwTR?= NEH5OHdUSU6JRWK=
TE-1 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LYTWlEPTB;NkS2MlEzKG6P NVX0XHJjW0GQR1XS
BT-474 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjJZ4xRUUN3ME22OFcvODZibl2= Moq4V2FPT0WU
KARPAS-45 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTZ2Nz62JI5O MWrTRW5ITVJ?
MOLT-16 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTZ2Nz65N{BvVQ>? M2G2RXNCVkeHUh?=
KURAMOCHI NUiyN4IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZ3Nz61NUBvVQ>? NUTlOIdYW0GQR1XS
K-562 MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXxWYV5UUN3ME22OlkvPTFibl2= NFfDWG1USU6JRWK=
EKVX MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXVc3F{UUN3ME22O|IvPzFibl2= NWLJXXlDW0GQR1XS
GAK NFPUTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S0ZWlEPTB;Nke1MlMhdk1? MXzTRW5ITVJ?
NCI-SNU-5 M2Tte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnDZ49KSzVyPU[5NE4xOSCwTR?= NV[2cpZNW0GQR1XS
NCI-H2126 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;j[3UzUUN3ME23NlYvQDdibl2= NFjXNGxUSU6JRWK=
CTV-1 NEXtUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrQNm9KSzVyPUe0OE46KG6P NVTLSmljW0GQR1XS
SW962 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLBUlJKSzVyPUe0PE41PCCwTR?= MWTTRW5ITVJ?
MONO-MAC-6 NFPaOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[zTWM2OD15NU[uPVMhdk1? MljDV2FPT0WU
NCI-H748 MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G0OGlEPTB;N{W4Mlk6KG6P MUnTRW5ITVJ?
NCI-H524 NIjpeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe4SIhRUUN3ME23PFAvPzNibl2= MljEV2FPT0WU
LS-123 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LnT2lEPTB;N{m1MlY6KG6P MUjTRW5ITVJ?
NB7 M4XPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rFTGlEPTB;OEG0MlE1KG6P MYnTRW5ITVJ?
LS-1034 M{XOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\BNnBKSzVyPUiyPE46QCCwTR?= NUiw[5RiW0GQR1XS
TE-5 NFTxSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP4flZKSzVyPUi4N{42PiCwTR?= MYDTRW5ITVJ?
A704 M1PLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHT[HBYUUN3ME24PVkvOTVibl2= Mn;kV2FPT0WU
TK10 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S2N2lEPTB;OUG2MlA{KG6P MWrTRW5ITVJ?
NCI-H345 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTEVHBOUUN3ME25OFMvOjJibl2= NFf5R3VUSU6JRWK=
CGTH-W-1 NHXqe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PmSmlEPTB;OUS4MlE{KG6P NEDXdZpUSU6JRWK=
NCI-H510A MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy1eoFTUUN3ME25PFUvOTJibl2= MUjTRW5ITVJ?
NCI-H1963 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;OTWM2OD1zLkCzNlkzKM7:TR?= NWDQWFBYW0GQR1XS
SCC-3 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwMEO0NVQh|ryP NHrLVHJUSU6JRWK=
EW-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXzTIZFUUN3ME2xMlA5PzR|IN88US=> M2\pfnNCVkeHUh?=
CPC-N NWC5e3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkflTWM2OD1zLkC4PEDPxE1? NH\pXXBUSU6JRWK=
NCI-H1417 NXH5ZlJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTRPYRVUUN3ME2xMlEzOjZizszN MULTRW5ITVJ?
DG-75 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDxTWM2OD1zLkG2Nlg2KM7:TR?= M3G4PXNCVkeHUh?=
HD-MY-Z MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT1TWM2OD1zLkG2OFE3KM7:TR?= NGH4NG5USU6JRWK=
ATN-1 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iwZ2lEPTB;MT6yOlIxQSEQvF2= NGDEdXdUSU6JRWK=
KM-H2 NHTONW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDWTGlZUUN3ME2xMlI3PDB6IN88US=> MV;TRW5ITVJ?
NCI-H2081 NW\SeZNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXhS4pKSzVyPUGuNlY3OzdizszN M{DQe3NCVkeHUh?=
HL-60 NI\GT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln5TWM2OD1zLkK2PVU6KM7:TR?= NWqy[I5nW0GQR1XS
DB MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13mXGlEPTB;MT6yO|I1OiEQvF2= M3y1V3NCVkeHUh?=
NCI-H1522 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT1Tm9KSzVyPUGuNlg5QDdizszN MXfTRW5ITVJ?
AM-38 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkSohKSzVyPUGuN|A4OiEQvF2= M1i0NnNCVkeHUh?=
NCI-H446 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LBVGlEPTB;MT6zNlEzOSEQvF2= MkOyV2FPT0WU
SU-DHL-1 NVO1eJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjm[Jh{UUN3ME2xMlMzQDBzIN88US=> MX7TRW5ITVJ?
NH-12 NGDS[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwM{[zO|Qh|ryP M2i0VXNCVkeHUh?=
DMS-79 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\R[WlEPTB;MT6zOlg3PiEQvF2= NVjoXGVQW0GQR1XS
NCI-H716 NWfBUGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TrfmlEPTB;MT6zPFk5PiEQvF2= NHT5[mtUSU6JRWK=
ML-2 NYriN4V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzkTWM2OD1zLkSxOVI6KM7:TR?= NUHQUWFHW0GQR1XS
NB10 M1nYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCwTWM2OD1zLkS2OlMzKM7:TR?= MX;TRW5ITVJ?
ONS-76 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrEO2ZsUUN3ME2xMlU{PTZ7IN88US=> M1fyeXNCVkeHUh?=
LOUCY M3jMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7JTWM2OD1zLkW0OlU4KM7:TR?= MkfkV2FPT0WU
SCLC-21H MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF61UHNKSzVyPUGuOVg2QDJizszN NYHCeVUyW0GQR1XS
TGW NVr6UXpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DLT2lEPTB;MT62N|k4PSEQvF2= M2\vcXNCVkeHUh?=
LXF-289 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\CNYVKSzVyPUGuO|MzPjhizszN MmfYV2FPT0WU
BB49-HNC MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vWcmlEPTB;MT63N|U5PiEQvF2= NEjwXXlUSU6JRWK=
NCI-H747 NFGwc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HB[mlEPTB;MT63OVM1PiEQvF2= NF7ZZpJUSU6JRWK=
LU-165 M4jFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHDUI14UUN3ME2xMlg1QTh4IN88US=> M3mzdXNCVkeHUh?=
OMC-1 NFrW[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLZXWJKSzVyPUGuPVUxPjZizszN MWLTRW5ITVJ?
RCC10RGB MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\LRm57UUN3ME2xMlk2QDF5IN88US=> M{XtOnNCVkeHUh?=
SW684 Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwOU[wPVkh|ryP NUWybnh6W0GQR1XS
TE-8 NH7JO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnSNppKSzVyPUKuNFU2PTlizszN NH;qS3lUSU6JRWK=
SK-N-DZ NX7rS5h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6wTWM2OD1{LkGzNlc1KM7:TR?= NFL2VFdUSU6JRWK=
EVSA-T M2XhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\2Z3c1UUN3ME2yMlE4OzF3IN88US=> MniwV2FPT0WU
KASUMI-1 NF;YXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXPOoU2UUN3ME2yMlE5QDF3IN88US=> NWPCbWxWW0GQR1XS
NKM-1 NH\lelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K5dmlEPTB;Mj6yOVQ4OiEQvF2= NHn1e45USU6JRWK=
CAL-148 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHYPYxKSzVyPUKuN|M3OTRizszN MX;TRW5ITVJ?
NCI-H64 NXrh[INGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP1O2F1UUN3ME2yMlM1OjN{IN88US=> MkDuV2FPT0WU
KNS-81-FD M2nUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC1eFRQUUN3ME2yMlM3PjJizszN MmOwV2FPT0WU
KM12 M2HnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nrUWlEPTB;Mj60NFg{QSEQvF2= NUPpRVFbW0GQR1XS
SW954 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\XTWM2OD1{LkS3O|c6KM7:TR?= MU\TRW5ITVJ?
NCI-H1395 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0R2lEPTB;Mj61NlY1PSEQvF2= M3fsfnNCVkeHUh?=
DJM-1 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHkdHU2UUN3ME2yMlYxPjNizszN NIrCT|JUSU6JRWK=
COLO-668 NF\x[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLqXoZsUUN3ME2yMlgzPjl3IN88US=> NVPaO4tGW0GQR1XS
NCI-H1436 NFP1dohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrmVo1KSzVyPUKuPFU3OTVizszN NH3UT2dUSU6JRWK=
LB2241-RCC MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPP[FVXUUN3ME2yMlg3QDN7IN88US=> M1XucHNCVkeHUh?=
GT3TKB NXjndHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjjfVFKSzVyPUKuPFkxPTVizszN MnLuV2FPT0WU
COLO-824 M1TheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTKTWM2OD1{Lki5O|Y5KM7:TR?= Mn7kV2FPT0WU
ES1 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j0S2lEPTB;Mj64PVg4QSEQvF2= MWjTRW5ITVJ?
LB771-HNC NH6zS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjITWM2OD1{LkmwPVQ3KM7:TR?= NFzIWplUSU6JRWK=
GI-ME-N NXLXNGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz4TWM2OD1|LkCwPVA1KM7:TR?= MYnTRW5ITVJ?
NALM-6 NF3Kd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCzW29KSzVyPUOuNFA6OzNizszN MX7TRW5ITVJ?
LU-134-A M3jlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf1WmpKSzVyPUOuNFU1OjVizszN NF;6[YxUSU6JRWK=
DMS-153 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLlbnZQUUN3ME2zMlA2QDJ2IN88US=> M3;TOXNCVkeHUh?=
MZ1-PC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTNwMEmwO|gh|ryP NX[yVXN7W0GQR1XS
NCI-H1155 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjsTWM2OD1|LkGxOlEh|ryP M1vJUXNCVkeHUh?=
CAS-1 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwMUO3NFch|ryP NXfQcJpYW0GQR1XS
D-502MG NFHZdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\6cItKSzVyPUOuNVQ{QSEQvF2= MmjYV2FPT0WU
NCI-H2141 NE\BR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf1TWM2OD1|LkG3OFUzKM7:TR?= M{nt[XNCVkeHUh?=
NB6 M3fLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1fJBsUUN3ME2zMlE5OjV7IN88US=> M{flTnNCVkeHUh?=
NCCIT MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LHfWlEPTB;Mz6yNVgxQSEQvF2= NWe5XYpPW0GQR1XS
NB69 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjG[Y1NUUN3ME2zMlMyQDlzIN88US=> Ml;oV2FPT0WU
JVM-2 NVflSGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYflOHI5UUN3ME2zMlM3PDN|IN88US=> NH36XldUSU6JRWK=
K052 M4rMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzhXmNKSzVyPUOuN|c6PjhizszN MYrTRW5ITVJ?
HCC2157 NXLUU3NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr5bmxKSzVyPUOuOVMzOjhizszN M2T1UXNCVkeHUh?=
KMOE-2 NFP2VXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TLbmlEPTB;Mz61OFI1OiEQvF2= NUmw[pZlW0GQR1XS
SF268 M1Wx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrtdFBKSzVyPUOuO|E2PTRizszN NFzBNHNUSU6JRWK=
CHP-126 NYXIN2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\qZmlEPTB;Mz63OlQ2QCEQvF2= NEPqWoNUSU6JRWK=
CP66-MEL NVLDZXRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qzW2lEPTB;Mz63PVA6PCEQvF2= NF\XOodUSU6JRWK=
NCI-H69 M1fIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\kSGlEPTB;ND6wNVk{PiEQvF2= MUPTRW5ITVJ?
A253 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzDR|J2UUN3ME20MlAzOTBzIN88US=> MorHV2FPT0WU
NB14 NYTRRol{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnZTWM2OD12LkGwOFc6KM7:TR?= NHKyV3dUSU6JRWK=
NCI-H1694 NYrmXGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDPSVFKSzVyPUSuNVMyOTJizszN MVnTRW5ITVJ?
NCI-H2196 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KwSWlEPTB;ND6xO|E3QSEQvF2= MYTTRW5ITVJ?
TE-9 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\sPHhKSzVyPUSuNVc2QDJizszN MoDhV2FPT0WU
D-283MED M3fo[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf4TFBKSzVyPUSuNVg5PCEQvF2= MoDTV2FPT0WU
OCI-AML2 NH7IOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrFUphLUUN3ME20MlE6PDh7IN88US=> NVKxc4pDW0GQR1XS
D-263MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnrUJNEUUN3ME20MlIzQTZzIN88US=> MWLTRW5ITVJ?
MPP-89 NX;mdlh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;sVG1KSzVyPUSuNlc{ODRizszN NVWxRlN3W0GQR1XS
LAMA-84 NV3aV3NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwM{C0NlEh|ryP NFi4[HRUSU6JRWK=
LB373-MEL-D NYfzVJZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrMNpV7UUN3ME20MlM3Pzh7IN88US=> MnriV2FPT0WU
UACC-257 NELuZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPjTWM2OD12LkO5OVM1KM7:TR?= NUPsXYRCW0GQR1XS
MC-CAR NIPRSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCxTWM2OD12LkSzPVkh|ryP NW\COGtVW0GQR1XS
COLO-320-HSR M{DPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzsVlNKSzVyPUSuOFQ1OjdizszN MWTTRW5ITVJ?
P30-OHK MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHSeJFQUUN3ME20MlY3PThzIN88US=> NWf5elF4W0GQR1XS
UACC-812 MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDwblBKSzVyPUSuOlkyPjFizszN NG\FSmpUSU6JRWK=
CTB-1 MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjOTWM2OD12LkexOVU2KM7:TR?= NYPFXVdlW0GQR1XS
ALL-PO Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;1PHFKSzVyPUSuPFQxPzdizszN NVrLSndUW0GQR1XS
SK-MEL-2 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL4TWM2OD12Lki2PVU2KM7:TR?= MVjTRW5ITVJ?
TC-YIK NUTH[oxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwOUe5OFIh|ryP NV3vb29JW0GQR1XS
NCI-H1882 M3vvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOwUplUUUN3ME21MlAzODBzIN88US=> M{Th[nNCVkeHUh?=
MHH-CALL-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n2Z2lEPTB;NT6wOVA1OiEQvF2= NV7QdmVoW0GQR1XS
U-87-MG NGCzZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3keFFKSzVyPUWuNFk1PjZizszN MXHTRW5ITVJ?
NCI-H1092 NX7idY5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;C[mlEPTB;NT6yOlU2PSEQvF2= MoHVV2FPT0WU
TE-441-T MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe4TWM2OD13LkK3PFIh|ryP M{nzWnNCVkeHUh?=
SK-MEL-1 NHrFZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXKTWM2OD13LkK5NFQ1KM7:TR?= M4HPZXNCVkeHUh?=
EW-22 NHH3cFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MormTWM2OD13LkK5OFY3KM7:TR?= NV3Ybo5wW0GQR1XS
MZ7-mel MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXUIw2UUN3ME21MlQxPjlzIN88US=> NYHpXo1bW0GQR1XS
LP-1 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPRTWM2OD13LkSxNlkyKM7:TR?= MnX2V2FPT0WU
NCI-SNU-16 M{DheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17CTGlEPTB;NT62OFA4PCEQvF2= NVrycG5FW0GQR1XS
LU-65 NVqx[pZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTVwN{[zO|Mh|ryP MXLTRW5ITVJ?
CW-2 NFHlcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HMWmlEPTB;NT64OVk2QSEQvF2= M1\zfHNCVkeHUh?=
WSU-NHL NXzY[2txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rySmlEPTB;NT65OVE4PCEQvF2= NV3mXGFsW0GQR1XS
IST-MES1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:wfWlEPTB;NT65OVQ1OyEQvF2= M3;2fnNCVkeHUh?=
U-266 NGrSSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;wPY5KSzVyPUWuPVgzODJizszN M4rZW3NCVkeHUh?=
TALL-1 NUHGeYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPVXIFvUUN3ME22MlE1Pjh6IN88US=> MlzzV2FPT0WU
Calu-6 M1XB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MTWM2OD14LkG1N|E3KM7:TR?= MV3TRW5ITVJ?
MMAC-SF NIPSRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7qOmhKSzVyPU[uNVg2PTZizszN NYG4TlhHW0GQR1XS
NCI-H82 NFTHRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3UWlEPTB;Nj6yNFQ5QSEQvF2= MWnTRW5ITVJ?
RS4-11 NGXad|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy1V3JKSzVyPU[uNlU5QTdizszN NH;QdG1USU6JRWK=
SNU-C2B NXz5WHV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTZwNEC5Olkh|ryP NUHRPGJHW0GQR1XS
BOKU MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13nXGlEPTB;Nj60O|U6PyEQvF2= M33IeXNCVkeHUh?=
C8166 NH;STndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\H[mlEPTB;Nj61OVkyOiEQvF2= M13nbHNCVkeHUh?=
D-247MG M1\NPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nJe2lEPTB;Nz6wOFM1PyEQvF2= NFnB[4VUSU6JRWK=
EW-18 M1zNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjHTWM2OD15LkC3NlkzKM7:TR?= MUXTRW5ITVJ?
KG-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3YV4NbUUN3ME23MlYzPzN6IN88US=> MVLTRW5ITVJ?
REH MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PrWGlEPTB;Nz62PFExQSEQvF2= NYnReWh3W0GQR1XS
U-698-M M3rvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HvdGlEPTB;Nz64OFMyPSEQvF2= NIDWOYxUSU6JRWK=
KP-N-RT-BM-1 NFX1fpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrjdZFiUUN3ME23Mlk{ODJ7IN88US=> MULTRW5ITVJ?
MS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDJTWM2OD15Lkm2NFQyKM7:TR?= M4S3fHNCVkeHUh?=
SNU-C1 M2Xie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdwOUixPVIh|ryP NECzdo5USU6JRWK=
SK-MM-2 M2W0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDwUIZ4UUN3ME24MlI3ODZ3IN88US=> M2rYVHNCVkeHUh?=
LAN-6 NX75boh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OwW2lEPTB;OD6zNFAxOSEQvF2= NEnKTodUSU6JRWK=
NEC8 NEnGVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTMUmptUUN3ME24MlMxPjlzIN88US=> Mle1V2FPT0WU
NCI-H1770 NUT3OIVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M172eGlEPTB;OD6zPFAxOiEQvF2= MoSzV2FPT0WU
D-336MG NHjWe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TJbGlEPTB;OD60NFEyPiEQvF2= M1[yenNCVkeHUh?=
COLO-829 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjiTWM2OD16LkS4PFc6KM7:TR?= MX3TRW5ITVJ?
LS-513 NX;CfFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny2TWM2OD16LkW5OVk6KM7:TR?= NEXEVYpUSU6JRWK=
YT MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLtTWM2OD16Lk[yOFI4KM7:TR?= MYHTRW5ITVJ?
EW-24 NWPmNlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRThwN{[1OEDPxE1? NFu5XoVUSU6JRWK=
IST-SL1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofXTWM2OD16Lki2OVQ{KM7:TR?= M1rMb3NCVkeHUh?=
CA46 M3fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjnTWM2OD16Lkm1NFk5KM7:TR?= MXzTRW5ITVJ?
NCI-H1838 NWDOZ3pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD4TWM2OD16Lkm4OlAzKM7:TR?= MlmyV2FPT0WU
NCI-H719 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjlTWM2OD17LkK1Nlc6KM7:TR?= NHzXWlhUSU6JRWK=
HCE-T MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LSUWlEPTB;OT6zNFg2OSEQvF2= NHvTb2xUSU6JRWK=
A498 NYDKZplTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTITWM2OD17LkO2NVI1KM7:TR?= M3LKZ3NCVkeHUh?=
LB831-BLC NY\yWHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTlwN{[1NlEh|ryP NHG2SJNUSU6JRWK=
SKM-1 NEnOWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTlwOEW5OlMh|ryP NVfaUY1xW0GQR1XS
THP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTlwOU[5NVgh|ryP NYPlcVcyW0GQR1XS
SHP-77 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPlcFdKSzVyPUGwMlQxPyEQvF2= M3f1[HNCVkeHUh?=
EW-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nLb2lEPTB;MUCuOlI5QSEQvF2= NEHOOo5USU6JRWK=
KY821 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n4cWlEPTB;MUCuO|Y{KM7:TR?= NEDBfnVUSU6JRWK=
NCI-SNU-1 NYjyXYlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4THdGlEPTB;MUGuNFIyPyEQvF2= NEnkeIJUSU6JRWK=
HCC2218 NF;R[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID6VIJKSzVyPUGxMlM6QDZizszN M{PTTXNCVkeHUh?=
IM-9 NGHNZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID5OlVKSzVyPUGxMlUyODZizszN MnLTV2FPT0WU
NCI-H889 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFzLkWzNVMh|ryP M1TJSnNCVkeHUh?=
HDLM-2 NVH3fng2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF{LkSxOVkh|ryP NYnEVnFiW0GQR1XS
LB2518-MEL M16xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jpTmlEPTB;MUKuOlgyPSEQvF2= M1TrT3NCVkeHUh?=
NCI-H23 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET3eYhKSzVyPUGzMlI1OjVizszN NH;PWnFUSU6JRWK=
NB17 M4raPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPLXZZxUUN3ME2xN{41PTd7IN88US=> NW\pPWx2W0GQR1XS
NCI-H322M MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jaUWlEPTB;MUSuOFA3QCEQvF2= MXHTRW5ITVJ?
SUP-T1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF2LkSxN{DPxE1? MVnTRW5ITVJ?
ES3 NEXJZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7CPVlrUUN3ME2xOU4xPzB|IN88US=> MmnHV2FPT0WU
ES5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nPZWlEPTB;MUWuNFc5PyEQvF2= MkDKV2FPT0WU
NCI-H1650 NWjYRXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTOTWM2OD1zNT60PVc6KM7:TR?= NH;vV41USU6JRWK=
NCI-H226 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe2WY5MUUN3ME2xOU45PzZ6IN88US=> NVHreJVxW0GQR1XS
COR-L88 M{fr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ToT2lEPTB;MU[uN|E1KM7:TR?= M1nXfHNCVkeHUh?=
SCC-15 NYDXc|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXKW4xWUUN3ME2xOk4{QDZ7IN88US=> NYXKT2s2W0GQR1XS
GOTO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTQTWM2OD1zNj60O|k{KM7:TR?= NH3R[m9USU6JRWK=
SIMA NYDUOGN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mweGlEPTB;MU[uOFgxOiEQvF2= MmDYV2FPT0WU
NCI-H1299 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrEUItKSzVyPUG3MlE2QTFizszN NUP1fWJRW0GQR1XS
NCI-H1581 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTpd5V3UUN3ME2xO{41OjF7IN88US=> NFPaeXpUSU6JRWK=
MHH-NB-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF5Lkm2PFMh|ryP NHixTINUSU6JRWK=
MFM-223 NY\4XG4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[wdnZjUUN3ME2xPE4xPTN6IN88US=> NWXzc3djW0GQR1XS
ES7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP1PXBRUUN3ME2xPE42PDNzIN88US=> NHjjVYpUSU6JRWK=
JVM-3 NFGxZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LMWWlEPTB;MUiuO|E4KM7:TR?= MnXxV2FPT0WU
RL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJyLkO4PEDPxE1? NYfob5JzW0GQR1XS
EC-GI-10 M2KzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13rUGlEPTB;MkGuNlA1OSEQvF2= M{XoWXNCVkeHUh?=
LNCaP-Clone-FGC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\NfWJKSzVyPUKxMlY4PjhizszN M4rPbnNCVkeHUh?=
IMR-5 M2G4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HrZWlEPTB;MkGuPFQ6PCEQvF2= M2LpdnNCVkeHUh?=
KP-N-YS MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ZeXpKSzVyPUKxMlg4PSEQvF2= MoDyV2FPT0WU
Mo-T NHjOOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITEVJZKSzVyPUKyMlIyQDVizszN NFHne2VUSU6JRWK=
NCI-H128 NHG1WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDqOXNxUUN3ME2yN{42QDV|IN88US=> Mli0V2FPT0WU
RH-1 NEPrd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ|Lke4OlYh|ryP M3rufnNCVkeHUh?=
NCI-H2171 NEfzVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ2LkK0PFUh|ryP NEfXNJdUSU6JRWK=
RPMI-8866 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG1TWM2OD1{Nj63OFIh|ryP NH:0bFhUSU6JRWK=
SK-N-FI MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJ5LkO4NVEh|ryP NGnJWHNUSU6JRWK=
LOXIMVI M2rKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ5LkiwOVEh|ryP MWXTRW5ITVJ?
P31-FUJ NH;acWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNzLkWzO|Qh|ryP M4[1OHNCVkeHUh?=
KMS-12-PE Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu0TWM2OD12OT61N|AzKM7:TR?= NHnoO3FUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID